Microsoft and Bristol Myers Squibb have partnered to improve early detection of lung cancer using AI-powered radiology tools.
Key Details
- 1The collaboration aims to leverage Microsoft's scalable AI imaging platform and BMS’s oncology expertise.
- 2Focus is on optimizing early detection and care pathways for non-small cell lung cancer patients.
- 3Targeted initiatives include addressing low adherence to follow-up and improving workflows for underserved populations.
- 4Lung cancer claims about 125,000 U.S. lives annually, but early diagnosis via low-dose CT reduces mortality risk.
- 5The partnership seeks to deliver scalable diagnostic tools and efficiency gains for healthcare organizations.
Why It Matters
Early lung cancer detection has a clear impact on patient survival, but screening adherence remains low. Integrating scalable AI radiology platforms with oncology expertise could significantly improve workflows, diagnosis, and patient outcomes, especially for underserved populations.
Source
Radiology Business
Related News
•Radiology Business
FDA Clears Median's Eyonis AI for CT Lung Cancer Screening
Median Technologies' Eyonis LCS, an AI tool for low-dose CT lung cancer screening, receives FDA clearance.
•AuntMinnie
Deep Learning Super-Resolution Boosts Accuracy of Coronary CT Angiography
Super-resolution deep learning reconstruction (SR-DLR) outperforms hybrid iterative reconstruction in coronary CT angiography for stenosis assessment.
•AuntMinnie
Task-Specific NLP Outperforms General LLMs for Lung Nodule Detection in Chest CT Reports
A radiology-trained NLP model significantly outperformed several general-purpose large language models in extracting incidental lung nodule data from chest CT reports.